Regulatory T cells (Tregs) have a fundamental function in monitoring the immune homeostasis in healthy individuals. In cancer and, in particular, in hematological malignancies, Tregs exert a major immunosuppressive activity, thus playing a critical role in tumor cell growth, proliferation, and survival. Here, we summarize published data on the prognostic significance of Tregs in hematological malignancies and show that they are highly conflicting. The heterogeneity of the experimental approaches that were used explains-at least in part-the discordant results reported by different groups that have investigated the role of Tregs in cancer. In fact, different tissues have been studied (i.e., peripheral blood, bone marrow, and lymph node), applying different methods (i.e., flow cytometry versus immunohistochemistry, whole blood versus isolated peripheral blood mononuclear cells versus depletion of CD25 + cells, various panels of monoclonal antibodies, techniques of fixation and permeabilization, and gating strategies). This is of relevance in order to stress the need to apply standardized approaches in the study of Tregs in hematological malignancies and in cancer in general.
Introduction
Regulatory T cells (Tregs) constitute a small-size subpopulation of CD4 + T cells, accounting for 1-4% of circulating CD4 + lymphocyte in humans, specialized in suppressive functions that control unwanted immune responses not only toward self-antigens but also toward foreign antigens in the context of the immune tolerance [1] .
Gershon and Kondo from Yale University first proposed the existence of CD8 + T cells with suppressive activity more than 40 years ago [2] . However, after the initial great interest following this first report, due to the fact that a precise definition of Tregs lacked for several years, no further advances in the study of this cell population were made for decades. In 1995, Sakaguchi and coworkers identified Tregs in mouse as CD4 + T cells expressing surface interleukin-2 (IL-2) receptor α-chain (CD25) [3] . Baecher-Allan and coworkers, using flow cytometry and analyzing sorted cells in vitro, identified a very small subset of T cells with high expression of CD25 and regulatory function in humans [4] . However, CD25 is not exclusively restricted to Tregs, and its surface expression is also seen on effector T lymphocytes after activation [5] . The intracytoplasmic Forkhead helix box P3 (FoxP3), a transcription factor required for the development, maintenance, and function of Tregs was subsequently identified [6, 7] . The central role of this transcription factor is confirmed by the fact that a FoxP3 single gene mutation on the X chromosome induces in Scurfy mice a severe autoimmune/inflammatory disease. In humans, the same mutation causes a disease called IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), characterized by autoimmune manifestations in multiple endocrine organs, such as diabetes and thyroiditis, inflammatory bowel disease, and severe allergies [8] . Finally, the absence of the heterodimeric IL-7 receptor (CD127) combined with CD4, CD25, and FoxP3, has been shown to better identify Tregs, avoiding the contamination from other cell populations such as activated effector T cells [9, 10] .
Regulatory T Cells and Prognostic Significance in Cancer
The role of Tregs in cancer appears to be relevant by promoting tumor progression and suppressing effective antitumor activity [11] [12] [13] . Overall, the large majority of studies report that the frequency and the suppressive function of Tregs are increased in cancer patients as compared to healthy subjects. However, some issues are still a matter of debate, in particular the prognostic significance of this cell subpopulation. In general, Tregs predict poor outcome in cancer patients [12] , but some reports have shown that higher Treg numbers and preserved activity are associated with a better prognosis [14] [15] [16] . This review stems from the need to reassess the topic of prognostic relevance of Tregs in cancer, focusing on patients with hematologic malignancies. For this purpose, we reviewed a large body of published papers conducting a PubMed literature search (keywords: Regulatory T cells, Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, multiple myeloma, monoclonal gammopathies, myelofibrosis, essential thrombocythemia, polycythemia vera, and Ph1-negative chronic myeloproliferative neoplasms).
Regulatory T Cells in Chronic Lymphocytic Leukemia
The accumulation of monoclonal B lymphocytes in the bone marrow, lymphoid organs, and peripheral blood is the hallmark of chronic lymphocytic leukemia (CLL), the most common form of leukemia in Western countries [17] . The importance of T cell dysregulation in the pathogenesis and development of CLL is now well established [18, 19] , and in this setting, the role of Tregs has also been investigated [20, 21] . As shown in Table 1 , several authors reported data on Tregs in CLL showing in the majority of cases an expansion of this population [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . In addition, a correlation between higher Treg numbers and more aggressive clinical-biological features and adverse prognosis of CLL has been described. As previously discussed [20] , the reported percentage of Tregs in CLL is highly variable. According to the majority of reports, the percentage of Tregs is higher in CLL patients than in normal controls, and when the absolute number is considered, Tregs are always found to be significantly greater in CLL as compared to healthy donors.
Interestingly, based on their experimental work, Jak et al. speculated that the accumulation of Tregs in CLL is due to an increased proliferation induced by CD27/CD70 interaction in the lymph node proliferation centers and to a decreased sensitivity to apoptosis [22] .
Dasgupta et al. tried to establish an optimal threshold level for prognostic purpose [28] . The cut-off was assessed by receiver operating characteristic (ROC) analysis. A cutoff of 5.7% and 35 cells/μL for percentage and absolute Treg count, respectively, were determined as optimal in patients with CLL, along with a median Tregs percentage of 15.5% used to separate low-and high-risk patients. Using the same approach in the setting of Rai stage 0 CLL patients, our group found that the absolute number of Tregs was an independent predictor of time to the first treatment, with the best predictive cut-off being 41 cells/μL [24] . Overall, these data show that the absolute Treg number is able to identify Rai stage 0 CLL patients at higher risk of requiring therapy.
Rissiek et al., applying a multidimensional scaling analysis to assess the composition of the circulating T cell populations, generated T cell scores showing that suppressive T cell profiles emerge early during monoclonal B cell lymphocytosis (MBL), the well-recognized pre-CLL stage [31] [32] [33] . As the disease evolves from MBL to overt and advanced CLL, specific sequential changes in T cells appear, progressively compromising the effector T cells function and contributing to disease progression [30] .
In our hands too, the absolute number of Tregs in MBL patients was lower compared to CLL patients, but slightly higher than healthy controls [30] . In addition, the absolute Treg cell number directly correlated with more advanced CLL clinical stages and higher circulating B cell numbers. Of note, the absolute number of Tregs was lower in MBL patients as compared to early-stage CLL patients (0/A according to Rai/Binet stage). In summary, Treg numbers increase gradually from normal subjects to "clinical" MBL patients and are significantly higher in CLL patients as compared to MBL patients.
Regarding the functional properties, some authors reported a reduced inhibitory function of Tregs in CLL [27, 34] . On the contrary, Piper et al. showed that in CLL patients Tregs retain their function and are not influenced by chemotherapy [35] . A correlation between a higher circulating Treg numbers and dysfunctional Vγ9Vδ2 T cells in untreated CLL patients was also shown, thus corroborating the hypothesis that Tregs may not be only bystanders but have a functional role in this setting [36] .
A normalization in Treg number was observed after fludarabine therapy [34] , and also in CLL patients treated with lenalidomide, suggesting that such drugs are able to modulate cell-mediated immunity in CLL [37] .
Finally, we also tested the ability of green tea, a popular beverage in China, Japan, and increasingly used in Western countries, to modulate Treg number in peripheral blood of CLL patients in the early phases of the disease, for which at the present time there is no effective intervention and a "wait and see" policy is generally adopted [38, 39] . We showed that the B cell lymphocyte count and the absolute circulating Treg number were reduced after 6-month consumption of oral green tea extract, suggesting that this compound can modulate circulating Tregs in CLL patients with early stage of disease and delay disease progression.
Regulatory T Cells in Lymphomas and Monoclonal Gammopathies
The neoplastic lymph nodes in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) contain not only neoplastic B cells but also nontumoral T cells, macrophages, and dendritic cells, constituting the so-called tumor microenvironment. The importance of the microenvironment in the pathogenesis and progression of lymphomas is still a matter of debate and many studies have focused on the role of its different components, including Tregs. Tregs are increased in lymphoma tissues and are able to inhibit cytotoxic CD8 + T cells exposed to lymphoma B cells [40] . Marshall et al. showed that HL-infiltrating lymphocytes are highly enriched in Tregs, which induce a profoundly immunosuppressive environment [41] . This was confirmed by Schreck et al. who demonstrated that in classical HL the microenvironment is dominated by Th2 cells and Tregs [42] . Moreover, a high ratio of Tregs over Th2 cells resulted in a significantly shortened disease-free survival.
However, conflicting results have been reported regarding the prognostic significance of Tregs infiltration in both HL and NHL. In fact, whereas in follicular lymphoma (FL), the most common form of low-grade NHL, germinal center (GC) diffuse large B cell lymphomas (DLBCL), and HL, an intrafollicular infiltration of Tregs, has a positive prognostic significance; this is not true in the case of non-GC-type DLBCL [43] . Moreover, as shown in Table 2 , in some reports, a higher number of Tregs correlates with a good prognosis, while in other, it does not [43] [44] [45] [46] [47] [48] [49] . Of interest, Kim et al. evaluating Tregs on node biopsy of extranodal natural killer/T cell lymphomas showed that patients with poor performance status and with non-upper aerodigestive tract had a decreased number of Tregs (<50/0.40 mm 2 ), while an increased number (>50/0.40 mm 2 ) was associated with prolonged overall survival and progression-free survival [48] . Finally, Carreras et al. reported that the median Treg number in patients with FL at diagnosis had a median cell percentage of 10.5% [49] . Furthermore, patients were classified as having Tregs > 10%, 5-10%, and <5% with a 5-year overall survival of 80%, 74%, and 50%, respectively. Patients with transformed DLBCL showed lower Treg number with respect to patients with grades 1-3 FL.
Regarding the frequency and prognostic significance of Tregs, conflicting results have also been obtained in the field of monoclonal gammopathies (Table 3) . In some reports, Tregs were found to be increased in frequency, while in others they were reduced or comparable with respect to healthy subjects [50] . Again, some authors reported a correlation with tumour burden and with worse prognosis, but this was not consistent among different publications [50] [51] [52] [53] [54] [55] [56] [57] . We recently published our data on the flow cytometric evaluation of Tregs in multiple myeloma (MM) and monoclonal gammopathies of undetermined significance (MGUS) [51] . We found no differences in Treg frequency in MM and MGUS with respect to normal controls, and no correlations with main clinical and laboratory features in this disease setting were observed. , and JAK2 V617F allelic burden was found, thus suggesting that the lack of ability of PegIFN-α treatment to decrease circulating Tregs predicts a poor molecular response.
Regulatory T Cells in Acute Leukemias
Primary myelofibrosis (PMF) is a clonal disease of the hematopoietic stem cell characterized by a variable degree of bone marrow fibrosis, splenomegaly, and an increased risk of leukemic transformation. Contradictory data about Tregs in PMF have been published (Table 6 ). Massa et al. reported a reduced frequency and absolute number of Tregs in PMF than in normal controls [68] . No association with clinicalbiological features of the disease was found, but a correlation between reduced Treg frequency and longer disease duration in patients with CALR mutation genotype was described. In these patients, a higher Treg frequency is significantly associated with advanced disease, higher IPSS/DIPSS score, and lower hemoglobin concentration. The same authors later documented the effect of ruxolitinib on Treg frequency, showing that the treatment with this small-molecule JAK1/2 inhibitor leads to a profound and long-lasting reduction in the frequency of circulating Tregs [69]. Wang et al. found no significant differences in the number of Tregs in patients with primary or post-ET myelofibrosis [70] . However, they reported that ruxolitinib significantly inhibits the release of sIL2-Rα, an inflammatory cytokine produced by Tregs, contributing to the clinical improvement of constitutional symptoms induced by the drug. These data have been further confirmed by an in vitro study in which the JAK1/2 inhibition by ruxolitinib was able to prevent Treg differentiation [71] . Table 6 summarizes the results of studies analyzing Tregs in Ph1-negative chronic myeloproliferative neoplasms.
Conclusions
Tregs have a fundamental function in maintaining the immune homeostasis in healthy individuals. In cancer and in particular in hematological malignancies, Tregs exert a major immunosuppressive activity, thus playing a critical role in tumor cell growth, proliferation, and survival. Published data on the prognostic significance of the Treg number in hematological malignancies show conflicting results. In our opinion, this variability reported by different groups is most likely explained by the heterogeneity of the experimental approaches that are used. In fact, different tissues have been studied (i.e., peripheral blood, bone marrow, and lymph node) and different analytic methodologies have been applied (i.e., flow cytometry versus immunohistochemistry). Moreover, while some authors studied the whole blood compartment, others evaluated the Treg population in isolated peripheral blood mononuclear cells or in a CD25-depleted subpopulation. Finally, various panels of markers, different techniques of fixation and permeabilization, and several gating strategies have been applied. This is of relevance to stress the need to apply standardized approaches in the study of Tregs in hematological malignancies and in cancer in general.
In perspective, in light of the increasing evidence of the important role of Tregs in immune evasion mechanism exerted by tumor cells, therapeutic interventions targeting intratumoral Treg infiltrates may be conceived in order to fight cancer. Treg inhibition or depletion, the latter uses monoclonal antibodies targeting surface antigens on Tregs such as CD25, is currently under investigation [72] .
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